ADAR1 inhibitor / Exelixis, STORM Therap - LARVOL DELTA

Exelixis Announces Third Quarter 2021 Financial Results and Provides Corporate Update (Businesswire) - "In October, Exelixis and STORM entered into an exclusive collaboration and license agreement under which the companies will discover and advance novel drug leads intended for the treatment of cancer. The collaboration will focus initially on ADAR1, advancing early work by STORM applying its proprietary RNA epigenetic platform, as well as explore an additional undisclosed target."

Licensing / partnership • Oncology